Save Product
Product Details
Synonyms
TGFBR2, TGFR2, TbetaR-II, TGFβR2
Source
Human TGF-beta RII, His Tag (TG2-H52H5) is expressed from human 293 cells (HEK293). It contains AA Thr 23 - Asp 159 (Accession # P37173-1).
Predicted N-terminus: Thr 23
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 17.4 kDa. The protein migrates as 25-45 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human TGF-beta RII, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human TGF-beta RII, His Tag (Cat. No. TG2-H52H5) is more than 95% and the molecular weight of this protein is around 20-30 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Serial dilutions of Human TGF-beta RII, His Tag (Cat. No. TG2-H52H5) were added into Human Latent TGFB1, His Tag (Cat. No. TG1-H524x) : Biotinylated Human TGF-beta RII, His,Avitag (Cat. No. TG2-H82E4) binding reactions. The half maximal inhibitory concentration (IC50) is 0.39287 μg/mL (QC tested).
Protocol
Customer Reviews Writing Reviews
A***n2022-07-30
LikesI ordered Acro’s human TGF-beta Receptor II for Octet kinetics binding assays for several assays. Delivery was extremely quick and customer service was very responsive to questions I had. I first used this TGF-beta RII in an Octet binding kinetics assay and received high quality results that were consistent with what I expected. I also used this product as a TGF-beta sink in cytotoxicity assays. I have been impressed by the quality of Acro’s products.
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Drug Development Progress- English Name：
Transforming growth factor beta receptor 2
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
8 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
